Silence Unveils Preliminary but Encouraging Phase I Data on Cancer Drug | GenomeWeb

By Doug Macron

Silence Therapeutics this week released preliminary results from an ongoing phase I study of its siRNA-based cancer drug Atu027. The drug has been well tolerated at dose levels tested so far, and data from one patient suggests the possibility of therapeutic benefit.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: effect of variants linked to body shape differs by age and sex, transcriptome differences in bats with and without white-nose syndrome, and more.

A researcher argues that big prizes like the Nobel or Lasker awards send the wrong message about research.

Maria Freire, the president of the Foundation for the National Institutes of Health, discusses recent genomics-fueled advances with The Open Mind's Alexander Heffner.

Three researchers win the Nobel Prize for their efforts to develop treatments for parasitic diseases.